Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Nephroprotection by antifibrotic and anti-inflammatory effects of the vasopeptidase inhibitor AVE7688.

Gross O, Koepke ML, Beirowski B, Schulze-Lohoff E, Segerer S, Weber M.

Kidney Int. 2005 Aug;68(2):456-63.

2.

Preemptive ramipril therapy delays renal failure and reduces renal fibrosis in COL4A3-knockout mice with Alport syndrome.

Gross O, Beirowski B, Koepke ML, Kuck J, Reiner M, Addicks K, Smyth N, Schulze-Lohoff E, Weber M.

Kidney Int. 2003 Feb;63(2):438-46.

3.

Nephroprotective effect of the HMG-CoA-reductase inhibitor cerivastatin in a mouse model of progressive renal fibrosis in Alport syndrome.

Koepke ML, Weber M, Schulze-Lohoff E, Beirowski B, Segerer S, Gross O.

Nephrol Dial Transplant. 2007 Apr;22(4):1062-9. Epub 2007 Feb 6.

4.

Vasopeptidase inhibitor restores the balance of vasoactive hormones in progressive nephropathy.

Benigni A, Zoja C, Zatelli C, Corna D, Longaretti L, Rottoli D, Maggioni P, Todeschini M, Noris M, Remuzzi G.

Kidney Int. 2004 Nov;66(5):1959-65.

5.

Antifibrotic, nephroprotective effects of paricalcitol versus calcitriol on top of ACE-inhibitor therapy in the COL4A3 knockout mouse model for progressive renal fibrosis.

Rubel D, Stock J, Ciner A, Hiller H, Girgert R, Müller GA, Gross O.

Nephrol Dial Transplant. 2014 May;29(5):1012-9. doi: 10.1093/ndt/gft434. Epub 2013 Nov 5.

6.

Vasopeptidase inhibition prevents target organ damage and improves survival in spontaneously hypertensive rats.

Linz W, Schäfer S, Afkham F, Gerl M, Schmidts HL, Rütten H.

J Renin Angiotensin Aldosterone Syst. 2006 Sep;7(3):155-61.

PMID:
17094052
7.

Antifibrotic, nephroprotective potential of ACE inhibitor vs AT1 antagonist in a murine model of renal fibrosis.

Gross O, Schulze-Lohoff E, Koepke ML, Beirowski B, Addicks K, Bloch W, Smyth N, Weber M.

Nephrol Dial Transplant. 2004 Jul;19(7):1716-23. Epub 2004 May 5.

8.

Loss of collagen-receptor DDR1 delays renal fibrosis in hereditary type IV collagen disease.

Gross O, Girgert R, Beirowski B, Kretzler M, Kang HG, Kruegel J, Miosge N, Busse AC, Segerer S, Vogel WF, Müller GA, Weber M.

Matrix Biol. 2010 Jun;29(5):346-56. doi: 10.1016/j.matbio.2010.03.002. Epub 2010 Mar 20.

PMID:
20307660
9.

Vasopeptidase inhibition normalizes blood pressure and restores endothelial function in renovascular hypertension.

Quaschning T, Hocher B, Ruhl S, Kraemer-Guth A, Tilgner J, Wanner C, Galle J.

Kidney Blood Press Res. 2006;29(6):351-9. Epub 2006 Nov 30.

PMID:
17139187
10.

Chronic renal failure and shortened lifespan in COL4A3+/- mice: an animal model for thin basement membrane nephropathy.

Beirowski B, Weber M, Gross O.

J Am Soc Nephrol. 2006 Jul;17(7):1986-94. Epub 2006 Jun 14.

11.

Renal protective effects of aliskiren beyond its antihypertensive property in a mouse model of progressive fibrosis.

Gross O, Girgert R, Rubel D, Temme J, Theissen S, Müller GA.

Am J Hypertens. 2011 Mar;24(3):355-61. doi: 10.1038/ajh.2010.231. Epub 2010 Dec 2.

PMID:
21127470
12.

Nephroprotection in Zucker diabetic fatty rats by vasopeptidase inhibition is partly bradykinin B2 receptor dependent.

Schäfer S, Schmidts HL, Bleich M, Busch AE, Linz W.

Br J Pharmacol. 2004 Sep;143(1):27-32. Epub 2004 Aug 2.

13.

Vasopeptidase inhibitor ilepatril (AVE7688) prevents obesity- and diabetes-induced neuropathy in C57Bl/6J mice.

Coppey L, Davidson E, Lu B, Gerard C, Yorek M.

Neuropharmacology. 2011 Feb-Mar;60(2-3):259-66. doi: 10.1016/j.neuropharm.2010.09.008. Epub 2010 Sep 16.

14.

Beneficial and adverse renal and vascular effects of the vasopeptidase inhibitor omapatrilat in renovascular hypertensive rats.

Wenzel UO, Wolf G, Jacob I, Schwegler C, Qasqas A, Amann K, Helmchen U, Stahl RA.

Nephrol Dial Transplant. 2003 Oct;18(10):2005-13.

15.

The vasopeptidase inhibitor AVE7688 ameliorates Type 2 diabetic nephropathy.

Schäfer S, Linz W, Vollert H, Biemer-Daub G, Rütten H, Bleich M, Busch AE.

Diabetologia. 2004 Jan;47(1):98-103. Epub 2003 Nov 14.

PMID:
14618238
16.

Hepatocyte growth factor counteracts transforming growth factor-beta1, through attenuation of connective tissue growth factor induction, and prevents renal fibrogenesis in 5/6 nephrectomized mice.

Inoue T, Okada H, Kobayashi T, Watanabe Y, Kanno Y, Kopp JB, Nishida T, Takigawa M, Ueno M, Nakamura T, Suzuki H.

FASEB J. 2003 Feb;17(2):268-70. Epub 2002 Dec 3.

17.

Norcantharidin ameliorates proteinuria, associated tubulointerstitial inflammation and fibrosis in protein overload nephropathy.

Liu FY, Li Y, Peng YM, Ye K, Li J, Liu YH, Duan SB, Ling GH, Xu XQ, Zhou LT.

Am J Nephrol. 2008;28(3):465-77. doi: 10.1159/000112850. Epub 2008 Jan 4.

PMID:
18176075
18.

[Protective effects of Hirsutella sinensis on renal interstitial fibrosis: experiment with rat model of chronic aristolochic acid nephropathy].

Zhu YF, Chen YP, Rui HL, Dong HR, Hu Z.

Zhonghua Yi Xue Za Zhi. 2007 Oct 16;87(38):2667-71. Chinese.

PMID:
18167239
19.

Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor AVE7688 in humans.

Azizi M, Bissery A, Peyrard S, Guyene TT, Ozoux ML, Floch A, Ménard J.

Clin Pharmacol Ther. 2006 Jan;79(1):49-61.

PMID:
16413241
20.

Mycophenolate mofetil slows progression in anti-thy1-induced chronic renal fibrosis but is not additive to a high dose of enalapril.

Krämer S, Loof T, Martini S, Rückert M, Wang Y, Böhler T, Shimizu F, Kawachi H, Neumayer HH, Peters H.

Am J Physiol Renal Physiol. 2005 Aug;289(2):F359-68. Epub 2005 Mar 15.

Items per page

Supplemental Content

Write to the Help Desk